

Developing the future of cancer treatment

Fighting cancer by local killing of tumor cells and activation of the immune system



Disclaimer

This presentation (the "Presentation") has been prepared by Lytix Biopharma AS ("Company") exclusively for information purposes.

The Presentation is being made only to, and is only directed at, persons to whom such presentation may lawfully be communicated ('relevant persons'). Any person who is not a relevant person should not act or rely on the Presentation or any of its contents.

The Presentation does not constitute an offering of securities or otherwise constitute an invitation or inducement to any person to underwrite, subscribe for or otherwise acquire securities in the Company. The release, publication or distribution of the Presentation in certain jurisdictions may be restricted by law, and therefore persons in such jurisdictions into which this Presentation is released, published or distributed should inform themselves about, and observe, such restrictions.

The Presentation contains certain forward-looking statements relating to the business, products, financial performance and results of the Company and/or the industry in which it operates. Forward-looking statements concern future circumstances and results and other statements that are not historical facts, sometimes identified by the words "believes", "expects", "predicts", "intends", "projects", "plans", "estimates", "aims", "foresees", "anticipates", "targets", and similar expressions. The forward-looking statements contained in the Presentation, including assumptions, opinions and views of the Company or cited from third party sources are solely opinions and forecasts which are subject to risks, uncertainties and other factors that may cause actual events to differ materially from any anticipated development. Neither the Company nor its employees provides any assurance that the assumptions underlying such forward-looking statements are free from errors nor does any of them accept any responsibility for the future accuracy of the opinions expressed in the Presentation or the actual occurrence of the forecasted developments. The Company assumes no obligation, except as required by law, to update any forward-looking statements or to conform these forward-looking statements to its actual results.

The Presentation contains information obtained from third parties. You are advised that such third-party information has not been prepared specifically for inclusion in the Presentation and the Company has not undertaken any independent investigation to confirm the accuracy or completeness of such information.

An investment in the Company involves risk, and several factors could cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements that may be expressed or implied by statements and information in the Presentation, including, among others, the risk factors described in the Company's information document dated 14 June 2021. Should any risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in the Presentation.

No representation or warranty (express or implied) is made as to, and no reliance should be placed on, any information, including projections, estimates, targets and opinions, contained herein, and no liability whatsoever is accepted as to any errors, omissions or misstatements contained herein, and, accordingly, neither the Company nor its directors or employees accepts any liability whatsoever arising directly or indirectly from the use of the Presentation.

By attending or receiving the Presentation you acknowledge that you will be solely responsible for your own assessment of the market and the market position of the Company and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the Company's business.

The Presentation speaks as of November 26, 2024. Neither the delivery of this Presentation nor any further discussions of the Company with any of the recipients shall, under any circumstances, create any implication that there has been no change in the affairs of the Company since such date.

Lytix Biopharma approaching commercialization and the final step

Novel, unique and innovative technology



Lytix technology **already proven**

Hybrid of **improved chemotherapy** and **modern immunotherapy**

Based on world leading research on molecules derived from nature's defense system

Robust portfolio of clinical studies



Targeting different types of **skin cancer**

Currently **3 ongoing phase II studies**

Expanding into deep seated cancer

Strong phase II results in basal cell carcinoma



Led by licensing partner Verrica Pharmaceuticals

Most common cancer type worldwide

97 % Overall Response rate (ORR)
Complete tumor elimination in 51% of the patients

Verrica has successfully raised \$42M+
Next step: End-of-Phase II meeting with FDA

Technology validated by strong clinical results in several studies

World leading research on molecules
derived from nature's defense system

Two product
candidates:

Lead candidate




Phase II asset



Preclinical-stage asset

Promising Phase II results in **heavily pre-treated** patients
with late-stage melanoma




Before: 2,8 cm non-treated tumor


Day 547: no tumor

- Disease control in 40% of the patients with stabilization of the disease up to 20 months
- Impressive effects in **both treated and non-treated tumors**

Very positive Phase II results in Basal Cell Carcinoma
("BCC") patients



Overall response
rate (ORR)



Overall reduction
of tumor size




Complete clearance of
basal cell carcinomas

“ *LTX-315 has the potential to be **utilized as first-line therapy*** ”

- Survey among BCC clinicians

Lytix has significantly reduced its development risk...



...and this has been our strategy

**Stand out in
the crowd**



Differentiate

**Adress an
unmet need**



Large commercial
potential

**Build brick
by brick**



Biotech and cancer drug
development is time
consuming and risky

**Stay close to
your markets**



The US is the biggest
market globally

**Alignment with
Big Pharma**



Swimming with
the tide

**Work with
the best**




Word-leading experts
within the organization

Stand out in the crowd: Hybrid of unique cancer cell killing and stimulation of the immune system

1


Directly injecting the cancer drug into the tumor

Untreated tumor



2

Broad activation of immune cells to target remaining tumors



Address an unmet need - with a defined commercial potential


CHALLENGE

Majority of cancer patients have “cold” tumors and therefore don’t respond to current immunotherapy



SOLUTION

Lytix technology convert «cold» tumors to «hot» tumors that respond better to immune therapy

Tumor **before** treatment



Tumor **after** treatment with LTX-315



- Therapies that address shortcomings of current Immunotherapy (immune checkpoint inhibitors) are highly needed
- Market for other immunotherapies is estimated to ~**USD 50bn** within 2028

Lytix is targeting large increasing markets

BASAL CELL CARCINOMA (BCC)




US INCIDENCE (annual) 3.6 million

- Global market 2021: \$6,7 Billion
- CAGR: 7,9%
- Projected global market 2028: \$11,5 Billion

PHASE II COMPLETED

MELANOMA



GLOBAL INCIDENCE (annual) 0,33 million

- Global market 2021: \$4,2 Billion
- CAGR: 11,97%
- Projected global market 2030: \$11,9 Billion

PHASE II ONGOING

DEEP SEATED CANCERS



GLOBAL INCIDENCE (annual) 0,9 million

Global market 2023: \$2.7 Billion
CAGR: 11,8 %

Projected global market 2032: \$7,6 Billion

PHASE I PLANNED

The groundwork is done - Building brick-by-brick over many years puts Lytix in an attractive position

Years of Scientific Research:

- Rigorous scientific documentation and collaborations to explore how our drug works

Small clinical studies to:

- Learn to optimize administration of LTX-315
- Document how LTX-315 addresses the shortcomings of current immunotherapy
- Identify the right cancer types for LTX-315
- Explore the right combination with other types of immunotherapy



Identified clinical strategy:

- Skin cancer - Monotherapy
- Early-stage cancer – Combination therapy

Stay close to key markets: The US is the biggest market globally



US oncology market

In global comparison, United States is expected to generate the highest revenue in the oncology drugs market, with an estimated USD 103.9 billion in 2024¹

Lytix already well established in US and key markets

- Licensing deal with Verrica Pharmaceuticals (US)
- The healthcare-focused investment firm, PBM Capital (US), largest shareholder in Lytix
- ATLAS-IT-05 Phase II clinical study initiated in the US
- Several Lytix employees/consultants located in the US
- Strong presence at some of the largest cancer conferences to showcase, learn and build network
- Advisory board with top global immuno-oncologists (US)

Our approach is aligned with the key priorities of big pharma



“ We are actively seeking partnerships with biopharma, academic, and clinical institutions to find **novel intratumoral therapies**, accelerate asset development, and shape future research through collaboration and investment

Intratumoral therapies are on the rise across the industry


Treating the whole body with drugs (systemic therapy) can cause harmful side effects. By treating directly in the tumors (intratumoral therapy) side-effects are reduced.

Companies leading the global intratumoral cancer therapies market:



Strong expected growth in the global intratumoral cancer therapies market

(USD billion)



Lytix is recognized by the best - and working with the best

Lytix' recognized by experts in the field. Strong advisory board help **optimizing and developing efficient studies**, whilst **opening doors to world-leading hospitals and institutions**, setting up Lytix in an attractive position

Scientific validation at renowned institutions



**NATIONAL
CANCER
INSTITUTE**



**Weill Cornell
Medicine**



**HARVARD
UNIVERSITY**

50+ publications in peer reviewed journals

Excellent Advisors



Dr. Jim Allison

- Nobel prize Winner 2018
- Founder of modern immunotherapy



Dr. Pam Sharma

- Leading clinical oncologist at MD Anderson
- Co-Director of the Parker Institute



Dr. Aurelien Marabelle

- Clinical Director of the Cancer Immunotherapy Program
- Leading expert on intratumoral immunotherapies at Gustave Roussy

Working with top clinicians at renowned cancer hospitals

THE UNIVERSITY OF TEXAS
**MD Anderson
Cancer Center**

Making Cancer History®

**GUSTAVE/
ROUSSY**
CANCER CAMPUS
GRAND PARIS

Executing on our strategy – upcoming important events

● Verrica - BCC

- FDA- End of Phase 2 meeting (**H1 2025**)
- **Phase III study next major milestone**

● Study in early-stage Melanoma patients initiated

- Interim results (**H1 2025**)

● Next drug candidate for deep seated cancer

- LTX-401 meeting with regulatory authorities (**Q4 2024**)



Lytix Biopharma's roadmap to create shareholder value



Non-metastatic skin cancer

LTX-315: Clear path towards commercialization, demonstrated through licensing with Verrica for several types of skin cancer

Milestone payments and royalties secured for future revenue streams

Metastatic skin cancer

LTX-315: Phase II results in early-stage melanoma
Interim data H1 2025
Final results H1 2026

Start dialog with mid-size/big pharma H2-2025 - 2026

Deep seated cancer

LTX-401: For deep seated tumors
Technology partly validated by LTX-315

Start dialog with mid-size/big pharma H2 2025 - 2026

Why Invest – Our value proposition

1

Unique technology

Hybrid of cancer cell killing and stimulation of the immune system
Address major challenges and unmet need in cancer therapy

2

Strategically positioned in a large and growing market

The market for immunotherapies is growing at pace, our intratumoral technology fit Big Pharma strategies and identified focus areas

3

Well equipped for future growth

International support and validation both from the pharmaceutical industry and academic communities. Already strong foothold in the important US market

4

Several upcoming value inflecting milestones

NeoLIPA study initiated early November and interim results H2 2025 in early-stage patients with a stronger immune system. Potential Ph. III study in BCC

Thank you!

Contact information:

Øystein Rekdal, CEO

oystein.rekdal@lytixbiopharma.com

Gjest Breistein, CFO

gjest.breistein@lytixbiopharma.com